Structural and immunogenic characteristics of goose parvovirus virus-like particles

IF 2.6 3区医学 Q3 VIROLOGY

Virology Pub Date : 2026-02-01 Epub Date: 2025-11-19 DOI:10.1016/j.virol.2025.110727

Junyi Li , Qi Yang , Zhibo Yang , Yangnan Huyan , Yi Xiong , Miao Sun , Yueping Zhang , Xinzheng Zhang , Geng Meng

{"title":"Structural and immunogenic characteristics of goose parvovirus virus-like particles","authors":"Junyi Li , Qi Yang , Zhibo Yang , Yangnan Huyan , Yi Xiong , Miao Sun , Yueping Zhang , Xinzheng Zhang , Geng Meng","doi":"10.1016/j.virol.2025.110727","DOIUrl":null,"url":null,"abstract":"<div><div>Goose parvovirus (GPV) is a highly lethal infectious pathogen primarily affecting goslings under one month old, with infection resulting in nearly 100 % mortality. However, no recombinant vaccine has been proven effective in preventing GPV infection. This study aims to structurally characterize GPV virus-like particles (VLPs) produced from <em>Saccharomyces cerevisiae</em> using cryo-electron microscopy (Cryo-EM) and three-dimensional reconstruction, to explore potential binding receptors, and to preliminarily verify the immunogenicity of GPV VLPs. The results show that GPV VLPs produced from <em>Saccharomyces cerevisiae</em> have the correct conformation and structural assembly, share structural features common to the <em>Parvoviridae</em> family and exhibits significant sequence and structural similarity to adeno-associated virus (AAV). The results of ELISA demonstrated that GPV doesn't bind to sialic acid (SIA), heparan sulfate proteoglycan (HSPG) and homolog of AAV receptor (AAVR) in vitro. Additionally, our animal trials demonstrate that GPV VLPs produced from <em>Saccharomyces cerevisiae</em> can trigger effective protection for geese from GPV infection. This study investigates the structural and immunological characteristics of GPV VLPs, presenting an innovative approach for the development of efficacious and cost-effective genetically engineered vaccines.</div></div>","PeriodicalId":23666,"journal":{"name":"Virology","volume":"614 ","pages":"Article 110727"},"PeriodicalIF":2.6000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0042682225003411","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Goose parvovirus (GPV) is a highly lethal infectious pathogen primarily affecting goslings under one month old, with infection resulting in nearly 100 % mortality. However, no recombinant vaccine has been proven effective in preventing GPV infection. This study aims to structurally characterize GPV virus-like particles (VLPs) produced from Saccharomyces cerevisiae using cryo-electron microscopy (Cryo-EM) and three-dimensional reconstruction, to explore potential binding receptors, and to preliminarily verify the immunogenicity of GPV VLPs. The results show that GPV VLPs produced from Saccharomyces cerevisiae have the correct conformation and structural assembly, share structural features common to the Parvoviridae family and exhibits significant sequence and structural similarity to adeno-associated virus (AAV). The results of ELISA demonstrated that GPV doesn't bind to sialic acid (SIA), heparan sulfate proteoglycan (HSPG) and homolog of AAV receptor (AAVR) in vitro. Additionally, our animal trials demonstrate that GPV VLPs produced from Saccharomyces cerevisiae can trigger effective protection for geese from GPV infection. This study investigates the structural and immunological characteristics of GPV VLPs, presenting an innovative approach for the development of efficacious and cost-effective genetically engineered vaccines.

Abstract Image

查看原文本刊更多论文

鹅细小病毒样颗粒的结构和免疫原性特征。

鹅细小病毒（GPV）是一种高度致命的传染性病原体，主要影响一个月以下的雏鹅，感染导致近100%的死亡率。然而，没有任何重组疫苗被证明能有效预防GPV感染。本研究旨在利用低温电子显微镜（Cryo-EM）和三维重建技术对酿酒酵母（Saccharomyces cerevisiae）生产的GPV病毒样颗粒（VLPs）进行结构表征，探索潜在的结合受体，初步验证GPV病毒样颗粒的免疫原性。结果表明，产自酿酒酵母的GPV VLPs具有正确的构象和结构组装，具有细小病毒科的结构特征，与腺相关病毒（adeno-associated virus， AAV）具有显著的序列和结构相似性。ELISA结果表明，GPV在体外不与唾液酸（SIA）、硫酸肝素蛋白多糖（HSPG）及AAV受体（AAVR）同源物结合。此外，我们的动物试验表明，由酿酒酵母生产的GPV VLPs可以有效地保护鹅免受GPV感染。本研究探讨了GPV VLPs的结构和免疫学特性，为开发有效且具有成本效益的基因工程疫苗提供了一种创新方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Virology 医学-病毒学

CiteScore

6.00

自引率

0.00%

发文量

157

审稿时长

50 days

期刊介绍： Launched in 1955, Virology is a broad and inclusive journal that welcomes submissions on all aspects of virology including plant, animal, microbial and human viruses. The journal publishes basic research as well as pre-clinical and clinical studies of vaccines, anti-viral drugs and their development, anti-viral therapies, and computational studies of virus infections. Any submission that is of broad interest to the community of virologists/vaccinologists and reporting scientifically accurate and valuable research will be considered for publication, including negative findings and multidisciplinary work.Virology is open to reviews, research manuscripts, short communication, registered reports as well as follow-up manuscripts.